Loading
A phase 1/2 trial of Capecitabine, Trastuzumab, Pertuzumab and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor is a phase 1/2 interventional study registered as NCT07140393 by Jiangsu HengRui Medicine Co., Ltd., with 120 participants planned, started 2025-10-28 and due to reach its primary completion in 2027-10. Interventions recorded: HRS-4508+ Capecitabine, HRS-4508+ Trastuzumab, HRS-4508+ Trastuzumab+ Pertuzumab, HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel, HRS-4508+ Trastuzumab + Nab-paclitaxel and HRS-4508+ Trastuzumab+ Capecitabine.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Pertuzumab, Jiangsu Hengrui Pharmaceuticals, Trastuzumab and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Capecitabine and the tag pipeline.